Matches in UGent Biblio for { <https://biblio.ugent.be/publication/535586#aggregation> ?p ?o. }
Showing items 1 to 35 of
35
with 100 items per page.
- aggregation classification "A1".
- aggregation creator B448142.
- aggregation creator B448143.
- aggregation creator B448144.
- aggregation creator B448145.
- aggregation creator B448146.
- aggregation creator person.
- aggregation date "2009".
- aggregation format "application/pdf".
- aggregation hasFormat 535586.bibtex.
- aggregation hasFormat 535586.csv.
- aggregation hasFormat 535586.dc.
- aggregation hasFormat 535586.didl.
- aggregation hasFormat 535586.doc.
- aggregation hasFormat 535586.json.
- aggregation hasFormat 535586.mets.
- aggregation hasFormat 535586.mods.
- aggregation hasFormat 535586.rdf.
- aggregation hasFormat 535586.ris.
- aggregation hasFormat 535586.txt.
- aggregation hasFormat 535586.xls.
- aggregation hasFormat 535586.yaml.
- aggregation isPartOf urn:issn:0264-410X.
- aggregation language "eng".
- aggregation title "Reduced detection and levels of protective antibodies to hepatitis B vaccine in under 2-year-old HIV positive South African children at a paediatric outpatient clinic".
- aggregation abstract "The study evaluated and compared the prevalence of anti-HBs and exposure to hepatitis B virus (HBV) in vaccinated South African babies aged between 5 and 24 months from the Expanded Programme on Immunisation clinic [EPI group] and paediatric outpatient clinic [OPD group], and results were stratified by HIV status. A total of 303 (243 EPI group and 60 OPD group) babies were studied. All sera were tested for anti-HBs, HBsAg and anti-HBc, while IgM anti-HBc and HBV DNA were only tested in samples positive for HBsAg and/or and-HBc. Overall, there was a gross difference in the prevalence of anti-HBs marker between the EPI and OPD groups. The EPI group demonstrated higher levels of seroconversion (89.3% vs. 81.7%; p = 0.105) and seroprotection rates (86.0% vs. 75.0%; p = 0.038), compared to the OPD babies. When the overall results were stratified by HIV status, seroprotection was 85.7% for the HIV-negatives and 78.1% for the HIV-positives, although this was not statistically significant (p=0.125). The seroprotection rates were almost comparable between the HIV-positives (84.3%; n = 51) and the HIV-negatives (86.5%; it = 192) (p = 0.695) in the EPI group. In contrast, reduced seroprotection rates were observed between the HIV-positives (63.6%; n = 22) and HIV-negatives (81.6%; n = 38) in the OPD group, although this was not statistically significant (p=0.123). Interestingly, no HBsAg or anti-HBc marker was detected in the OPD group, compared to total exposure rate of 4.9% (HBsAg carriage was 1.2%) in the EPI group.".
- aggregation authorList BK781172.
- aggregation endPage "151".
- aggregation issue "1".
- aggregation startPage "146".
- aggregation volume "27".
- aggregation aggregates 535597.
- aggregation isDescribedBy 535586.
- aggregation similarTo j.vaccine.2008.10.004.
- aggregation similarTo LU-535586.